Adverse effects of medical cannabinoids : a systematic review T. Wang, J-P. Collet, S. Shapiro, M.A. Ware, Canadian Medical Association Journal, 2008,178,13, 1669-1678 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2413308/pdf/20080617s00017p1669.pdf Abstract Background : The therapeutic use of cannabis and cannabisbased medicines raises safety concerns for patients, clinicians, policy-makers, insurers, researchers and regulators. Although the efficacy of cannabinoids is being increasingly demonstrated in randomized controlled trials, most safety information comes from studies of recreational use. Methods : We performed a systematic review of safety studies of medical cannabinoids published over the past 40 years to create an evidence base for cannabis-related adverse events and to facilitate future cannabis research initiatives. We critically evaluated [...]
Lire la suiteThe Intricate Influence of the Placebo Effect on Medical Cannabis and Cannabinoids J. Gertsch Medical Cannabis and Cannabinoids, 2018, 1, 60-64. Preclinical Science and Clinical Studies – Commentary DOI: 10.1159/000489291 https://www.karger.com/Article/Pdf/489291 Abstract The botanical drug cannabis flos (inflorescence of Cannabis sativa L.) has a unique popular status as being a potent recreational drug and bona fide universal remedy (panacea). Generally, cannabinoids exert therapeutic effects in a broad range of pathophysiologies related to inflammation, pain, metabolic and stress-related conditions in preclinical animal models. However, the translation of such data to humans still lacks an evidence-based foundation. Motivated by the booming cannabis manufacturing industry and the increasing worldwide self-therapy [...]
Lire la suiteLower-Risk Cannabis Use Guidelines : A Comprehensive Update of Evidence and Recommendations, B. Fisher, C. Russel, P. Sabioni et al., American Journal of Public Health, 2017, 107, 8, e1-e12. Écrit par des praticien canadiens, une excellente synthèse sur le thème des pratiques de Réduction des Risques chez les usagers de Cannabis, particulièrement les sujets jeunes, dans le contexte de la légalisation du Cannabis au Canada. avec une bibliographie de 224 références ! https://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2017.303818 https://ajph.aphapublications.org/doi/pdf/10.2105/AJPH.2017.303818 (PDF) et le flyer de RDR Cannabis des Canadiens : https://www.camh.ca/-/media/files/pdfs---reports-and-books---research/canadas-lower-risk-guidelines-cannabis-pdf.pdf
Lire la suitehttps://www.ncbi.nlm.nih.gov/books/NBK425767/ The Health Effects of Cannabis and Cannabinoids The Current State of Evidence and Recommendations for Research National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. Washington (DC): National Academies Press (US); 2017 Jan 12. ISBN-13: 978-0-309-45304-2ISBN-10: 0-309-45304-6 Copyright and Permissions Hardcopy Version at National Academies Press Significant changes have taken place in the policy landscape surrounding cannabis legalization, production, and use. During the past 20 years, 25 states and the District of Columbia have legalized cannabis and/or cannabidiol (a component of cannabis) for [...]
Lire la suiteJ Nat Prod. 2016 Feb 26;79(2):324-31. doi: 10.1021/acs.jnatprod.5b00949. Epub 2016 Feb 2. Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes. Aizpurua-Olaizola O1,2, Soydaner U1, Öztürk E1, Schibano D1, Simsir Y1, Navarro P2, Etxebarria N2, Usobiaga A2. Author information 1 Aifame GmbH , Tüfi 450, 9105 Wald-Schönengrund, Switzerland. 2 Analytical Chemistry Department, University of the Basque Country (UPV/EHU) , Barrio Sarriena s/n, 48940 Leioa, Spain. Abstract The evolution of major cannabinoids and terpenes during the growth of Cannabis sativa plants was studied. In this work, seven different plants were selected: three each from chemotypes I and III [...]
Lire la suitehttps://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/renseignements-medecins/renseignements-destines-professionnels-sante-cannabis-cannabinoides.html Renseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes (Version PDF - 2,690 Ko) Plante séchée ou fraîche et huile destinées à l'administration par ingestion ou par d'autres moyens Agent psychoactif Le présent document a été préparé par la Direction générale de la légalisation et réglementation du cannabis de Santé Canada pour fournir des renseignements sur l'usage du cannabis (marihuana) et des cannabinoïdes à des fins médicales. Le présent document est un résumé d'articles scientifiques examinés par les pairs et de revues internationales sur les utilisations thérapeutiques possibles et sur les effets néfastes du cannabis et des [...]
Lire la suiteInt J Drug Policy. 2015 Jan;26(1):20-9. doi: 10.1016/j.drugpo.2014.09.005. Epub 2014 Sep 17. Cannabis for therapeutic purposes and public health and safety: a systematic and critical review. Sznitman SR1, Zolotov Y2. Author information 1 School of Public Health, University of Haifa, Eshkol Tower, Room 705, Mt. Carmel, 3190501 Haifa, Israel. Electronic address: sznitman@research.haifa.ac.il. 2 School of Public Health, University of Haifa, Eshkol Tower, Room 705, Mt. Carmel, 3190501 Haifa, Israel. Abstract BACKGROUND: The use of Cannabis for Therapeutic Purposes (CTP) has recently become legal in many places. These policy and legal modifications may be related to changes in cannabis perceptions, availability and use and in the way [...]
Lire la suiteMedical Consequences of Cannabis Use Jag H. Khalsa, MS, PhD and Ruben Baler, PhD National Institute on Drug Abuse, National Institutes of Health, Bethesda, Janvier 2019 Disclaimer: The opinions in this paper are of authors and do not reflect the position of the National Institute on Drug Abuse, National Institutes of Health. Abstract Consumed by an estimated 2.5% of the world’s population, cannabis is the most popular illicit drug. Depending on age of onset, frequency, duration, and other variables, cannabis use can be associated with a broad spectrum of medical consequences, the range of which mirrors the physiological ubiquity and versatility of the endocannabinoid [...]
Lire la suiteMedical cannabis and mental health : A guided systematic review. Walsh Z1, Gonzalez R2, Crosby K3, S Thiessen M3, Carroll C3, Bonn-Miller MO4. Clin Psychol Rev., 2017 Feb, 51, 15-29. doi: 10.1016/j.cpr.2016.10.002. Abstract This review considers the potential influences of the use of cannabis for therapeutic purposes (CTP) on areas of interest to mental health professionals, with foci on adult psychopathology and assessment. We identified 31 articles relating to the use of CTP and mental health, and 29 review articles on cannabis use and mental health that did not focus on use for therapeutic purposes. Results reflect the prominence of mental [...]
Lire la suite2020 : De Cannabis Bono, INGOLD F.R., KAPLAN C.D., SUEUR C., Annales Médico-Psychologiques, 2020, 178, 296-302. 2018 : Le trouble stress post-traumatique et son traitement : au sujet d’une observation, F-R. INGOLD, C.D. KAPLAN, C. SUEUR, Intervention au Colloque UFCM I-care, Paris, Hôpital de La Salpétrière, 1er juin 2018. 2018 : Des cannabinoïdes et des hommes, Docteur Rodolphe Ingold, janvier 2018 2015 : INGOLD, F.R. ; SUEUR,C. ; KAPLAN,C.D. : Contribution à une exploration des propriétés thérapeutiques du cannabis, Annales Medico-Psychologiques, 173, 2015, 453-459. https://www.researchgate.net/publication/275672267_Contribution_a_une_exploration_des_proprietes_therapeutiques_du_cannabis 1998 : INGOLD, F.R. ; TOUSSIRT, M. : Le cannabis en France, préface du Professeur Roger HENRION, Ed. Anthropos, 1998.
Lire la suite